CRISPR Therapeutics AG (CRSP) Announces October 19th IPO
In the last twelve months, CRISPR Therapeutics AG generated $1.5 million in revenue and had a net loss of $44.2 million. CRISPR Therapeutics AG has a market-cap of $636 million.
Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager.
CRISPR Therapeutics AG provided the following description of their company for its IPO: “We are a leading gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR) Associated protein-9 and is a revolutionary technology for gene editing, the process of precisely altering specific sequences of genomic DNA. We are applying this technology to treat a broad set of rare and common diseases by disrupting, correcting or regulating disease-related genes. “.
CRISPR Therapeutics AG was founded in 2013 and has 77 employees. The company is located at 111 Eighth Avenue, New York, NY 10011, US and can be reached via phone at (212) 894-8800 or on the web at https://www.crisprtx.com.
Receive News & Stock Ratings for CRISPR Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics AG and related stocks with our FREE daily email newsletter.